Table. 2.
Laboratory findings of the two patients with severe COVID-19 pneumonia on admission to hospital
| Patient 1 | Patient 2 | |
|---|---|---|
| Blood routine | ||
| White blood cell count (*109/L, 3.5~9.5) | 3.01 | 12.13 |
| Neutrophils (*109/L, 1.8~6.3) | 1.52 | 10.61 |
| Neutrophils percent (%, 40.0~75.0) | 50.5 | 87.3 |
| Lymphocytes (*109/L, 1.1~3.2) | 1.05 | 0.67 |
| Lymphocytes percent (%, 20.0~50.0) | 34.9 | 5.5 |
| Blood biochemistry | ||
| Alanine aminotransferase (U/L, ≤ 41) | 18 | 12 |
| Aspartate aminotransferase (U/L, ≤ 40) | 41 | 12 |
| Creatinine (μmol/L, 59~104) | 67 | 51 |
| Urea (mmol/L, 3.6~9.5) | 4.20 | 4.10 |
| Lactate dehydrogenase (U/L, 135~225) | 297 | 317 |
| Albumin (g/L, 35~52) | 37.4 | 39.6 |
| Globulin (g/L, 20~35) | 24.6 | 32.5 |
| Infection-related biomarkers | ||
| Procalcitonin (ng/mL, 0.02~0.05) | 0.08 | 0.10 |
| C-reactive protein (mg/L, < 1 mg/L) | ||
| Prior to prednisolone 40 mg bid | 7.9 | 139.3 |
| 2nd day after treatment | 54.1 | – |
| 4th day after treatment | 3 | 8 |
| TNF-α (pg/ml, < 8.1) | 5.8 | 9.1 |
| Interleukin-1β (pg/ml, < 5.0) | < 5.0 | 51.0 |
| Interleukin-6 (pg/ml, < 7.0) | ||
| Prior to prednisolone 40 mg bid | 66.23 | 139.00 |
| After treatment | 3.18 (Day 22) | 3.39 (Day 20) |
| Coagulation function | ||
| D-dimer (μg/ml FEU, < 0.5) | 0.22 | 2.65 |
| Prothrombin time (s, 11.5~14.5) | 13.3 | 14.6 |
| Activated partial thromboplastin time (s, 29.0~42.0) | 45.2 | 39.0 |
| AMI indexes | ||
| Creatine kinase, MB Form (ng/mL, ≤ 7.2) | 1.1 | 1.2 |
| Cardiac troponin I (pg/mL, ≤ 34.2) | 4.5 | 4.0 |
| Myoglobin (ng/mL, ≤ 154.9) | 95.9 | 23.4 |
| N-terminal pro-B-type natriuretic peptide (pg/mL, < 241) | 849 | 414 |
| Partial pressure of oxygen (mmHg, 80~100) | 79.0 | 78.8 |
| Oxygen saturation (%, 95~99) | 93 (10 L/min) | 96 (10 L/min) |
| Confirmed date by real-time RT-PCR | 2020 Feb 11 | 2020 Feb 07 |